IRD (Opus Genetics) Cash per Share: $0.84 (As of Mar. 2026)

Author:

Vera Yuan

Director of Data and Quant Analytics at GuruFocus

Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.

View Profile →

Reviewed by:

Charlie Tian

Founder & CEO of GuruFocus

Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

View Profile →

Opus Genetics Inc IRD

24 GF Score

Price $3.26

GF Value $0.36

Valuation Significantly Overvalued

4 Warning Signs

View Full Analysis

What is Opus Genetics Cash per Share?

Opus Genetics IRD -0.30% 24 Cash per Share is $0.84 as of Mar. 2026. GuruFocus rates IRD with a GF Score™ of 24/100 and a GF Value™ of $0.36 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Opus Genetics's Cash per Share for the quarter that ended in Mar. 2026 was $0.84.

Opus Genetics (NAS:IRD) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Opus Genetics Cash per Share Related Terms

Opus Genetics Cash per Share Historical Data

* Premium members only.

The historical data trend for Opus Genetics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Opus Genetics Cash per Share Chart

Opus Genetics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Cash per Share

Get a 7-Day Free Trial

1.31

2.05

2.11

0.96

0.65

Opus Genetics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Cash per Share	Get a 7-Day Free Trial															0.92	0.54	0.48	0.65	0.84

24GF Score

Opus Genetics Inc IRD

Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Opus Genetics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Opus Genetics's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	45.091	/	69.90
	=	0.65

Opus Genetics's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	59.959	/	71.40
	=	0.84

Frequently Asked Questions Learn more about Cash per Share →

What does a Cash per Share of $0.84 mean?

Opus Genetics (IRD) has a Cash per Share of $0.84 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Opus Genetics and its competitors.

Is Opus Genetics' Cash per Share too high?

Opus Genetics' current Cash per Share is $0.84. Overall, Opus Genetics has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Opus Genetics' Cash per Share compare to PALI and VSTM?

Opus Genetics' Cash per Share of $0.84 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Cash per Share for a Biotechnology company?

A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Cash per Share mean?

A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Opus Genetics and its competitors. Opus Genetics's current Cash per Share is $0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Opus Genetics stock overvalued right now?

Based on GuruFocus' analysis, Opus Genetics (IRD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.36, compared to a current price of $3.26 — trading 805.6% above its estimated fair value. The current Cash per Share is $0.84. Opus Genetics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Cash per Share calculated?

Cash per Share is calculated from a company's financial statements. For Opus Genetics (IRD), the current Cash per Share is $0.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Opus Genetics (IRD) Overvalued in 2026?

Based on GuruFocus' analysis, Opus Genetics stock appears to be overvalued. The current stock price of $3.26 is trading 805.6% above its estimated GF Value™ of $0.36. GuruFocus considers Opus Genetics to be Significantly Overvalued.

Key valuation signals for IRD:

Cash per Share: $0.84
GF Value™: $0.36 vs. price of $3.26 (805.6% above fair value)
GF Score™: 24/100 with 4 warning signs

No single metric tells the full story. See the IRD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Opus Genetics Business Description

Industry Healthcare Biotechnology

Comparable Companies PALI VSTM GALT CYDY ABEO LCTX NWBO VRXA PRLD SLNCF VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges R3X1:Germany

Address 8 Davis Drive, Suite 220, Durham, NC, USA, 27713

Website https://www.opusgtx.com

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

24GF Score

Get the complete analysis for IRD

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.26

Price

$0.36

GF Value

View IRD Analysis

See Cash per Share data for all stocks →